JPMorgan Asset Management AbbVie Inc. 8.3 amendment

Date : 14/02/2020 @ 11:57
Source : UK Regulatory (RNS & others)

JPMorgan Asset Management AbbVie Inc. 8.3 amendment

TIDMTTM

RNS Number : 0860D

JPMorgan Asset Management

14 February 2020

Ap19

Amendment

   FORM   8.3 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY   INFORMATION 
 
Name of person dealing      JPMorgan Asset Management 
 (Note 1) 
Company dealt in            AbbVie Inc. 
                            ========================= 
Class of relevant security  US$0.01 common stock 
 to which the dealings 
 being disclosed relate 
 (Note 2) 
                            ========================= 
Date of dealing             12 February 2020 
                            ========================= 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant

security   dealt   in   (Note   3) 
 
                                          Long                Short 
                             Number          (%)   Number           (%) 
                             =======  ====  ====  =========  ====  ==== 
                             18,808,964* 
(1) Relevant securities       1.27*               3,126 0.00 
                             ===================  ===================== 
(2) Derivatives (other 
 than options)               1,309 0.00            288,072 0.02 
                             ===================  ===================== 
(3) Options and agreements 
 to purchase/sell 
                             ===================  ===================== 
                             18,810,273* 
Total                         1.27*               291,198 0.02 
                             ===================  ===================== 
 
 

*In addition to the dealings in section 2a, there is an increase in the holding of 27 common stock due to a transfer.

(b) Interests and short positions in relevant securities of the company, other than the class dealt

  in   (Note   3) 
 
Class of relevant security:                Long                Short 
                              Number          (%)   Number           (%) 
                              =======  ====  ====  =========  ====  ==== 
(1) Relevant securities 
                              ===================  ===================== 
 
  (2) Derivatives (other 
  than options) 
                              ===================  ===================== 
 
  (3) Options and agreements 
  to purchase/sell 
                              ===================  ===================== 
Total 
                              ===================  ===================== 
 
 

Ap20

   1.       DEALINGS  (Note   4) 
   (a)      Purchases and sales 
 
 
  Purchase/sale           Number of relevant securities        Price per unit 
                                                                  (Note 5) 
   Purchase                       225                        96.3900 USD 
    Purchase                       70                         96.4374 USD 
    Purchase                      2,215                       96.4375 USD 
    Purchase                       60                         96.4377 USD 
    Purchase                     127,726                      96.4632 USD 
    Purchase                     22,400                       96.9750 USD 
    Purchase                       810                        96.9900 USD 
    Purchase                      1,123                       97.1009 USD 
    Purchase                     467,908                      97.1914 USD 
    Purchase                      8,000                       97.2010 USD 
    Purchase                        8                         97.2013 USD 
    Purchase                       65                         97.7900 USD 
 
      Sale                        8,967                       96.3014 USD 
      Sale                         43                         96.5300 USD 
      Sale                        1,250                       96.6172 USD 
      Sale                         17                         96.8000 USD 
      Sale                         136                        97.0274 USD 
      Sale                        6,300                       97.0491 USD 
      Sale                        3,157                       97.7900 USD 
                 ======================================  ==================== 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product name,  Nature of transaction  Number of relevant   Price per 
 e.g. CFD       (Note 6)               securities           unit 
                                       (Note 7)             (Note 5) 
 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,  selling, purchasing or varying 
 
 Product      Writing,      Number of     Exercise       Type,       Expiry         Option 
   name,      selling,      securities      price    e.g. American,   date    money paid/received 
 e.g. call   purchasing,     to which                   European                   per unit 
  option       varying      the option                    etc.                     (Note 5) 
                etc.       relates (Note 
                                7) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     5) 
 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction         Details      Price per unit 
 (Note 8)                                   (if applicable) 
                                            (Note 5) 
 
 

Ap21

   2.       OTHER  INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

   Is a Supplemental Form 8 attached?  (Note   9)                                              NO 
 
Date of disclosure            14 February 2020 
Contact name                  Daniel Swart 
                              ============================= 
Telephone number              0207 134 6168 
                              ============================= 
If a connected EFM, name      Allergan plc 
 of offeree/offeror with 
 which connected 
                              ============================= 
If a connected EFM, state     Financial Advisor to Allergan 
 nature of connection (Note    plc 
 10) 
                              ============================= 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEFLFELFSISLII

(END) Dow Jones Newswires

February 14, 2020 06:57 ET (11:57 GMT)

ADVFN Advertorial
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200402 16:31:12